The latest issue of the RaDaR Newsletter contains information about the recent NIHR Portfolio extension and details of up-coming events.
The Renal Association invites expressions of interest from its members for the position of Chair of the Rare Diseases Committee detailed below. The deadline for submission of a formal expression of interest is 13 May 2018.
Role Title: Chair of the Rare Diseases Committee (RDC)
Appointed by an Appointments Panel
Reporting To: Academic Vice President
Responsible To: Renal Association Trustees via the Renal Information Governance Board (RIGB)
Tenure: Three years
Start Date: June 2018 – Post Annual General Meeting
The chair of the Rare Disease Committee (RDC) has a key role in the development and delivery of the Rare Renal Disease strategy of the Renal Association (RA). They are responsible for all aspects of the Committee’s activity as well as oversight of the 25 Rare Disease Groups (RDGs). The Chair and committee work closely with and have strategic input into the operation management and development of the UK Registry for Rare Kidney Diseases (RaDaR). RaDaR is funded through capitation from each Renal Unit. The Chair will be the professional and public face of the RAs rare disease initiatives. The role of Chair of the RDC is supported by an Operations Manager, employed by the UK Renal Registry.
Development of the opportunities created by the RDC in establishing RaDaR is seen as a key strategic aim of the Renal Association.
This is an exciting opportunity to leverage clinical service and research opportunities offered by the large cohorts of patients with rare kidney diseases already collected by RaDaR. The research opportunities could be achieved by analysis of current cohort data, ‘Big data’ linkage and investigator led or pharma input into projects.
The role comprises 2 key areas of activity:
- Strategic input into the operational development of RaDaR
- Chairing the Rare Disease Committee and supporting clinical and research output from the RDGs
Responsibilities of the Role
- To prepare an annual business plan for the RDC
- To prepare written reports of the business of the RDC and delivery of the annual workplan for the Academic Affairs Board and Executive Committee
- To work with the AVP to encourage a culture of active research through each RDG.
- To act as an advocate for research, clinical progress and patient empowerment in rare kidney diseases both within the RA and with relevant external individuals and organisations
- To act as a conduit for exchange of ideas and innovation between the RDGs, other relevant individuals and organisations both within the Association and externally
- To convene and chair meetings of the RDC at least twice a year (be responsible for producing an Agenda and approving minutes) and maintain committee business using e-mail and telephone communications between meetings
- To support the Rare Disease Groups by monthly communications and regular engagement with RDG chairs and committees
- To attend the RA Executive Committee RIGB and Academic Affairs Board meetings (usually by TC).
- Ensure the RDGs provide as a minimum an annual report, patient information and evidence of activity through annual reports.
- To champion improvements in training in rare disease and development of service standards for rare diseases
- To ensure the Committee’s website area is kept up to date with information about the current Committee membership, minutes of meetings and other relevant documents
- To keep the membership of the RA informed of the Committee’s activities through the website, monthly news, and other communications channels.
- Active member of the Renal Association in good standing
- An interest in rare renal diseases
- Excellent communication skills
- Leadership experience.
- Track record of excellence in delivering clinical services for rare renal disease
- Membership of one of the rare disease groups
- Research experience in a rare renal disease
- Experience in patient and public involvement
- Experience in rare disease education and training.
For those considering this position we invite you to informally discuss it further with one of the following:
Please direct all formal expressions of interest in writing directly to the Renal Association Secretariat, via email email@example.com no later than the deadline of Sunday 13 May 2018. Candidates are asked to provide a maximum of a 1 side of A4 letter of application and a brief CV.
The Renal Association recognises and actively promotes the benefits of diversity. We welcome applications from all backgrounds, regardless of race, gender, disability, age, sexual orientation, religion or belief.
On Wednesday 28th February 2018 a joint patient and clinician event was held at the Queen Elizabeth Hospital, Birmingham to celebrate RaDaR’s achievements to date and consider where we go in the next ten years.
The Agenda, a report from the day and pdfs of the presentation can be found below.
RaDaR Meeting Agenda
RaDaR Meeting Report
RaDaR Introduction – Melanie Dillon
RaDaR Future – Detlef Bockenhauer>
Examples of research using RaDaR – Liz Colby
Membranous Nephropathy Presentation Paul Brenchley
Kidney Research UK – Sarah-Louise Harwood & Tracey Murray
Kidney Care UK – Fiona Loud
The latest copy of the RaDaR Newsletter contains important information about re-consenting paediatric patients as well as details of forthcoming events for Rare Disease Day (28th February) and World Kidney Day (8th March).
Due the severe adverse weather conditions and disruptions to transport, this meeting has unfortunately been postponed. Further updates will follow once a new date has been determined.
After over five highly successful years in the role, Dr Graham Lipkin is stepping down as lead for the Cystinosis Rare Disease Group and a replacement is now being sought.
This is a real opportunity to lead an enthusiastic group of clinicians, in partnership with patients and Industry, to support improvement in patient service, clinical care and research of an ultra-rare disease at an exciting time of drug development and change in service model.
Cystinosis Rare Disease Group Lead Advert